Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-337-3p mimic is a synthetic microRNA designed to replicate the activity of the endogenous microRNA-337-3p. In the context of oncology, specifically non-small cell lung cancer (NSCLC), it has been shown to sensitize cancer cells to taxane-based chemotherapy. The mimic exerts its effect by directly targeting and downregulating the expression of Signal Transducer and Activator of Transcription 3 (STAT3) and RAP1A, a member of the Ras oncogene family. This downregulation leads to an enhanced arrest of the cell cycle in the G2 phase when combined with taxanes, thereby overcoming drug resistance and reducing cell viability.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on miR-337-3p mimic.